143 related articles for article (PubMed ID: 27399001)
1. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
Arévalo MT; Huang Y; Jones CA; Ross TM
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a Chikungunya virus strain isolated from banked patients' sera.
Chalaem P; Chusri S; Fernandez S; Chotigeat W; Anguita J; Pal U; Promnares K
Virol J; 2016 Sep; 13(1):150. PubMed ID: 27590311
[TBL] [Abstract][Full Text] [Related]
4. Live-attenuated CHIKV vaccine with rearranged genome replicates in vitro and induces immune response in mice.
Tretyakova I; Joh J; Gearon M; Kraenzle J; Goedeker S; Pignataro A; Alejandro B; Lukashevich IS; Chung D; Pushko P
PLoS Negl Trop Dis; 2024 Apr; 18(4):e0012120. PubMed ID: 38648230
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease.
Broeckel RM; Haese N; Ando T; Dmitriev I; Kreklywich CN; Powers J; Denton M; Smith P; Morrison TE; Heise M; DeFilippis V; Messaoudi I; Curiel DT; Streblow DN
Front Immunol; 2019; 10():2563. PubMed ID: 31736977
[TBL] [Abstract][Full Text] [Related]
6. Chimeric alphavirus vaccine candidates for chikungunya.
Wang E; Volkova E; Adams AP; Forrester N; Xiao SY; Frolov I; Weaver SC
Vaccine; 2008 Sep; 26(39):5030-9. PubMed ID: 18692107
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials.
Rao S; Erku D; Mahalingam S; Taylor A
J Gen Virol; 2024 Feb; 105(2):. PubMed ID: 38421278
[No Abstract] [Full Text] [Related]
8. Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography.
Fox JM; Roy V; Gunn BM; Bolton GR; Fremont DH; Alter G; Diamond MS; Boesch AW
Front Immunol; 2023; 14():1153108. PubMed ID: 37251375
[TBL] [Abstract][Full Text] [Related]
9. Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine.
Tschismarov R; Zellweger RM; Koh MJ; Leong YS; Low JG; Ooi EE; Mandl CW; Ramsauer K; de Alwis R
JCI Insight; 2021 Nov; 6(21):. PubMed ID: 34582377
[TBL] [Abstract][Full Text] [Related]
10. Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.
Kramer RM; Zeng Y; Sahni N; Kueltzo LA; Schwartz RM; Srivastava IK; Crane L; Joshi SB; Volkin DB; Middaugh CR
J Pharm Sci; 2013 Dec; 102(12):4305-14. PubMed ID: 24129946
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of chikungunya virus infection associated with fatal outcomes.
de Souza WM; Fumagalli MJ; de Lima STS; Parise PL; Carvalho DCM; Hernandez C; de Jesus R; Delafiori J; Candido DS; Carregari VC; Muraro SP; Souza GF; Simões Mello LM; Claro IM; Díaz Y; Kato RB; Trentin LN; Costa CHS; Maximo ACBM; Cavalcante KF; Fiuza TS; Viana VAF; Melo MEL; Ferraz CPM; Silva DB; Duarte LMF; Barbosa PP; Amorim MR; Judice CC; Toledo-Teixeira DA; Ramundo MS; Aguilar PV; Araújo ELL; Costa FTM; Cerqueira-Silva T; Khouri R; Boaventura VS; Figueiredo LTM; Fang R; Moreno B; López-Vergès S; Mello LP; Skaf MS; Catharino RR; Granja F; Martins-de-Souza D; Plante JA; Plante KS; Sabino EC; Diamond MS; Eugenin E; Proença-Módena JL; Faria NR; Weaver SC
Cell Host Microbe; 2024 Apr; 32(4):606-622.e8. PubMed ID: 38479396
[TBL] [Abstract][Full Text] [Related]
12. A Divalent Chikungunya and Zika Nanovaccine with Thermostable Self-Assembly Multivalent Scaffold LS-SUMO.
Li Q; Zhang J; Deng Q; Liao C; Qian J; Chen Z; Lu J
Adv Healthc Mater; 2024 May; 13(13):e2303619. PubMed ID: 38340040
[TBL] [Abstract][Full Text] [Related]
13. Chikungunya virus cell-to-cell transmission is mediated by intercellular extensions in vitro and in vivo.
Yin P; Davenport BJ; Wan JJ; Kim AS; Diamond MS; Ware BC; Tong K; Couderc T; Lecuit M; Lai JR; Morrison TE; Kielian M
Nat Microbiol; 2023 Sep; 8(9):1653-1667. PubMed ID: 37591996
[TBL] [Abstract][Full Text] [Related]
14. A safe insect-based Chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques.
Adam A; Woolsey C; Lu H; Plante K; Wallace SM; Rodriguez L; Shinde DP; Cui Y; Franz AWE; Thangamani S; Comer JE; Weaver SC; Wang T
bioRxiv; 2024 May; ():. PubMed ID: 38826312
[TBL] [Abstract][Full Text] [Related]
15. Vaccine value profile for Chikungunya.
Flandes X; Hansen CA; Palani S; Abbas K; Bennett C; Caro WP; Hutubessy R; Khazhidinov K; Lambach P; Maure C; Marshall C; Rojas DP; Rosewell A; Sahastrabuddhe S; Tufet M; Wilder-Smith A; Beasley DWC; Bourne N; Barrett ADT
Vaccine; 2023 Nov; ():. PubMed ID: 38407992
[TBL] [Abstract][Full Text] [Related]
16. Characterization of chikungunya virus induced host response in a mouse model of viral myositis.
Dhanwani R; Khan M; Lomash V; Rao PV; Ly H; Parida M
PLoS One; 2014; 9(3):e92813. PubMed ID: 24667237
[TBL] [Abstract][Full Text] [Related]
17. Live-Attenuated CHIKV Vaccine with Rearranged Genome Replicates
Tretyakova I; Joh J; Lukashevich IS; Alejandro B; Gearon M; Chung D; Pushko P
bioRxiv; 2023 Sep; ():. PubMed ID: 37745520
[TBL] [Abstract][Full Text] [Related]
18. Chikungunya vaccine: Is it time for it?
Branda F; Scarpa F; Romano C; Ciccozzi A; Maruotti A; Giovanetti M; Ciccozzi M
J Med Virol; 2023 Dec; 95(12):e29341. PubMed ID: 38124664
[No Abstract] [Full Text] [Related]
19. Production of antigenically stable enterovirus A71 virus-like particles in
Kingston NJ; Snowden JS; Martyna A; Shegdar M; Grehan K; Tedcastle A; Pegg E; Fox H; Macadam AJ; Martin J; Hogle JM; Rowlands DJ; Stonehouse NJ
bioRxiv; 2023 Feb; ():. PubMed ID: 36778240
[TBL] [Abstract][Full Text] [Related]
20. Determining force of infection for chikungunya to support vaccine policy development.
Wilder-Smith AB; Wilder-Smith A
Lancet Infect Dis; 2024 May; 24(5):441-442. PubMed ID: 38342104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
